Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04574115
Other study ID # Omega Refractive Capsule VI
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 6, 2021
Est. completion date June 2024

Study information

Verified date March 2023
Source Omega Ophthalmics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and effectiveness of the investigational Omega Refractive Capsule (model VI)


Description:

This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design. Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - 40 years of age or older at the time of surgery diagnosed with bilateral cataracts - Able to understand and sign an informed consent - Willing and able to complete all study visits and assessments required for the study - Calculated lens power within the available range - Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present - Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation - Potential postop visual acuity of 20/25 or better in the judgment of the surgeon - Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography - Clear intraocular media other than cataract - Preop endothelial cell density of 2000 cells/mm2 or more Exclusion Criteria: - Subject's best corrected vision is light perception or no light perception in either eye - Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination. - Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos. - Eyelid abnormalities causing lagophthalmos. - Significant anterior blepharitis or meibomian gland dysfunction - Corneal abnormalities or conditions, other than regular topographic corneal astigmatism - Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium) - Abnormalities of the iris including trans-illumination defects - Pupil abnormalities (abnormally shaped, fixed or non-reactive) - Pharmacologic dilation less than 7 mm - Axial length <22.5mm - Lens thickness <4.1 mm - Anterior chamber depth <2.5mm - Prior ocular surgery - Epiretinal membrane - Macular edema - Retinal tears including operculated holes - Amblyopia - Glaucoma of any kind - Pseudoexfoliation syndrome - History of uveitis/iritis - Diabetic retinopathy - Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis). - Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax®, Flomaxtra®, Rapaflo®) or similar medications - Average Keratometry <38D or > 48D by topography - Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules. - History of ocular trauma - Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Omega Refractive Capsule with an FDA approved Intraocular Lens
Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
FDA approved Intraocular Lens
FDA approved Intraocular Lens

Locations

Country Name City State
Costa Rica Clinica 20/20 San José

Sponsors (1)

Lead Sponsor Collaborator
Omega Ophthalmics

Country where clinical trial is conducted

Costa Rica, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absence of fusion of peripheral anterior and posterior capsule slit lamp exam assessment 6 Month Postoperative Visit
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A